[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 32 of about 32
1. Enblad G, Hagberg H, Erlanson M, Lundin J, MacDonald AP, Repp R, Schetelig J, Seipelt G, Osterborg A: A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood; 2004 Apr 15;103(8):2920-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas.
  • Patients with peripheral T-cell lymphomas (PTLs) have an extremely poor prognosis when relapsed or refractory to conventional chemotherapy.
  • We have studied alemtuzumab, a humanized anti-CD52 monoclonal antibody, as therapy for patients with heavily pretreated and refractory PTL.
  • All had clinical stage III or IV disease.
  • Patients received a rapidly escalating dosage of alemtuzumab during the first week and, thereafter, 30 mg intravenously 3 times per week for a maximum of 12 weeks.
  • Five patients died of causes related to the treatment, in combination with advanced disease.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antibodies, Neoplasm / therapeutic use. Lymphoma, T-Cell, Peripheral / drug therapy
  • [MeSH-minor] Aged. Antibodies, Monoclonal, Humanized. Bone Marrow / drug effects. Drug Resistance, Neoplasm. Female. Humans. Infection / etiology. Male. Middle Aged. Pilot Projects. Recurrence

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15070664.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antibodies, Neoplasm; 3A189DH42V / alemtuzumab
  •  go-up   go-down


2. Jun HJ, Kim WS, Yang JH, Yi SY, Ko YH, Lee J, Jung CW, Kang SW, Park K: Orbital infiltration as the first site of relapse of primary testicular T-cell lymphoma. Cancer Res Treat; 2007 Mar;39(1):40-3
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital infiltration as the first site of relapse of primary testicular T-cell lymphoma.
  • The pathologic diagnosis of the radical orchiectomy specimen was peripheral T-cell lymphoma, unspecified (PTCL-u).
  • According to the Ann Arbor staging system, his initial stage was III because of the right nasopharyngeal involvement.
  • After first-line chemotherapy with four courses of the CHOP regimen and this was followed by involved-field radiotherapy, he achieved complete remission.
  • Although the patient received intensive chemotherapy with autologous hematopoietic stem cell transplantation, he ultimately died of leptomeningeal seeding.
  • Because both the central nervous system (CNS) and the orbit are sanctuary sites for chemotherapy, orbital infiltration of lymphoma should prompt physicians to evaluate involvement of the CNS and to consider performing prophylactic intrathecal chemotherapy as a treatment option.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ophthalmology. 1999 Nov;106(11):2109-20 [10571346.001]
  • [Cites] Eur J Cancer. 1994;30A(12):1760-4 [7880601.001]
  • [Cites] Am J Surg Pathol. 1994 Apr;18(4):376-90 [8141430.001]
  • [Cites] Histopathology. 1989 Aug;15(2):147-56 [2777217.001]
  • [Cites] Br J Urol. 1984 Oct;56(5):525-30 [6398719.001]
  • [Cites] Arch Ophthalmol. 1984 Mar;102(3):399-402 [6608342.001]
  • [Cites] Cancer. 2000 Jan 1;88(1):154-61 [10618618.001]
  • (PMID = 19746228.001).
  • [ISSN] 1598-2998
  • [Journal-full-title] Cancer research and treatment : official journal of Korean Cancer Association
  • [ISO-abbreviation] Cancer Res Treat
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2739356
  • [Keywords] NOTNLM ; Eye neoplasm / Non-Hodgkin's lymphoma / T cell lymphoma / Testes
  •  go-up   go-down


3. Pavone V, Gaudio F, Guarini A, Perrone T, Zonno A, Curci P, Liso V: Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma. Bone Marrow Transplant; 2002 Feb;29(4):285-90
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mobilization of peripheral blood stem cells with high-dose cyclophosphamide or the DHAP regimen plus G-CSF in non-Hodgkin's lymphoma.
  • Our study analyzes the mobilization of hematopoietic stem cells after two chemotherapeutic regimens in non-Hodgkin's lymphoma (NHL) patients.
  • Sixty-four patients (88.9%) had stage III-IV disease.
  • Mobilization chemotherapy regimens were randomly assigned as DHAP in 38 patients (52.7%) or cyclophosphamide (CPM) (5 g/m(2)) in 34 (47.2%) and the results of 132 procedures were analyzed.
  • At the time of PBSC mobilization, 46 patients (63.9%) were considered to be responsive (complete remission, partial remission or sensitive relapse) and 26 (36.1%) not responsive (refractory relapse or refractory to therapy).
  • Pre-apheresis CD34+ blood cell count and number of previous chemotherapy treatments were used to predict the total number of CD34+ cells in the apheresis product.
  • The mobilizing regimens (CPM or DHAP) were similar in achieving the threshold CD34+ cell yield, for optimal engraftment.
  • Since DHAP was very effective as salvage treatment, we suggest using DHAP as a mobilizing regimen in patients with active residual lymphoma at the time of stem cell collection.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols. Cisplatin. Cyclophosphamide / administration & dosage. Cytarabine. Dexamethasone. Granulocyte Colony-Stimulating Factor / administration & dosage. Hematopoietic Stem Cell Mobilization / methods. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Adolescent. Adult. Female. Hematopoietic Stem Cell Transplantation. Humans. Leukocyte Count. Male. Middle Aged. Prospective Studies. Transplantation, Autologous

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11896424.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 7S5I7G3JQL / Dexamethasone; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; DHAP protocol
  •  go-up   go-down


Advertisement
4. Kobayashi R, Yamato K, Tanaka F, Takashima Y, Inada H, Kikuchi A, Kumagai MA, Sunami S, Nakagawa A, Fukano R, Fujita N, Mitsui T, Tsurusawa M, Mori T, Lymphoma Committee, Japanese Pediatric Leukemia/Lymphoma Study Group: Retrospective analysis of non-anaplastic peripheral T-cell lymphoma in pediatric patients in Japan. Pediatr Blood Cancer; 2010 Feb;54(2):212-5
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Retrospective analysis of non-anaplastic peripheral T-cell lymphoma in pediatric patients in Japan.
  • BACKGROUND: Reports of non-anaplastic peripheral T-cell lymphoma (PTCL) in pediatric patients are relatively rare.
  • PROCEDURE: We performed a retrospective analysis in patients with PTCL over an 18-year period (1991-2008).
  • There were nine patients with PTCL, not otherwise specified (PTCL-NOS); ten with extranodal NK/T-cell lymphoma, nasal type; one with angioimmunoblastic T-cell lymphoma; and one with subcutaneous panniculitis-like T-cell lymphoma.
  • There were 12 patients with advanced stage disease (stages III and IV).
  • Chemotherapy and radiation was administered in 18 and 2 patients, respectively.
  • Among the two patients who did not receive chemotherapy and radiation, one patient died while being treated for HPS but another improved spontaneously.
  • CONCLUSIONS: Generally, the outcome results of conventional chemotherapy for high-risk PTCL are poor in adult patients.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / epidemiology. Lymphoma, T-Cell, Peripheral / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Infant. Japan / epidemiology. Male. Retrospective Studies. Stem Cell Transplantation. Survival Rate. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19856396.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


5. Takenaka K, Shinagawa K, Maeda Y, Makita M, Kozuka T, Ashiba A, Yamamoto K, Fujii N, Nawa Y, Hiramatsu Y, Sunami K, Ishimaru F, Yoshimo T, Kiura K, Harada M: High-dose chemotherapy with hematopoietic stem cell transplantation is effective for nasal and nasal-type CD56+ natural killer cell lymphomas. Leuk Lymphoma; 2001 Nov-Dec;42(6):1297-303
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose chemotherapy with hematopoietic stem cell transplantation is effective for nasal and nasal-type CD56+ natural killer cell lymphomas.
  • CD56+ natural killer (NK) cell lymphomas occur frequently in the nasal and nasopharyngeal regions and carry a poor prognosis.
  • We have studied seven cases with NK-cell lymphomas.
  • Six patients had localized (stage I or II) disease involving the nasopharyngeal region, while one had stage III disease.
  • One patient with stage I disease achieved a complete remission (CR) after treatment with involved-field irradiation, but subsequently relapsed and died.
  • The remaining six patients received combination chemotherapy as primary treatment: five patients with localized stage I or II disease and one patient with advanced stage III disease.
  • Responses to initial chemotherapy were generally poor.
  • These six patients received a variety of salvage chemotherapy regimens, but never achieved a CR.
  • Three of six patients received high-dose chemotherapy supported by syngeneic, autologous or allogeneic peripheral blood stem cell transplantation.
  • Our clinical experience suggests that myeloablative high-dose chemotherapy and bone marrow rescue by hematopoietic stem cell transplantation may be an effective salvage treatment modality for refractory NK-cell lymphomas and could be considered as a part of the initial therapy for these patients.
  • [MeSH-major] Antigens, CD56 / analysis. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Lymphoma, T-Cell / therapy. Nose Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Female. Humans. Killer Cells, Natural. Male. Middle Aged. Salvage Therapy

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11911411.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD56
  •  go-up   go-down


6. Cui XZ, Wang HQ, Liu XM, Zhang HL, Li W: [Treatment outcome and prognosis of autologous hematopoietic stem cell transplantation combined with high dose radiotherapy/chemotherapy in 22 patients with nasal NK/T cell lymphoma]. Zhonghua Xue Ye Xue Za Zhi; 2007 Sep;28(9):609-11
MedlinePlus Health Information. consumer health - Nasal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment outcome and prognosis of autologous hematopoietic stem cell transplantation combined with high dose radiotherapy/chemotherapy in 22 patients with nasal NK/T cell lymphoma].
  • OBJECTIVE: To analyze the outcome and prognosis of autologous hematopoietic stem cell transplantation (AHSCT) combined with high dose radiotherapy/chemotherapy in 22 patients with nasal NK/T cell lymphoma.
  • METHODS: From July 1992 to December 2005, 22 patients with nasal NK/T cell lymphoma were diagnosed pathologically.
  • The patients received cycles of chemotherapy every other two weeks or combined with radiotherapy for remission induction, followed high dose radiotherapy/chemotherapy, combined with autologous peripheral blood stem cell transplantation (APBSCT), or autologous bone-marrow transplantation (ABMT).
  • Twelve patients of IPI 3 -4 received consolidation chemotherapy, and one of them received the second transplantation.
  • The 5-year OS were as follows: for stage I - II and III - IV disease were 90.0% and 70.0% (P = 0.
  • Multivariate analysis by COX regression revealed that disease stage, B symptom and IPI were independent prognostic factors.
  • CONCLUSION: AHSCT combined with high dose radiotherapy/chemotherapy is an effective treatment for patients with poor prognosis nasal NK/T cell lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Lymphoma, Extranodal NK-T-Cell / therapy. Nose Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18246818.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


7. Martens C, Hodgson DC, Wells WA, Sun A, Bezjak A, Pintilie M, Crump M, Gospodarowicz MK, Tsang R: Outcome of hyperfractionated radiotherapy in chemotherapy-resistant non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys; 2006 Mar 15;64(4):1183-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of hyperfractionated radiotherapy in chemotherapy-resistant non-Hodgkin's lymphoma.
  • PURPOSE: Patients with chemotherapy-resistant lymphoma have rapidly progressive disease and a poor prognosis.
  • The radiation dose was 39.9-40.5 Gy in 30 fractions.
  • The median treatment time was 22 days with twice-daily involved-field RT.
  • The initial diagnosis was Stage I-II in 56% and Stage III-IV in 44%.
  • The histologic features at diagnosis were follicular in 11 (Grade 1 in 4, Grade 2 in 3, and Grade 3 in 4), diffuse large B-cell in 14, peripheral T-cell lymphoma in 2, Burkitt-like in 1, mantle cell in 2, natural killer cell in 2, plasmacytoma/lymphoma in 1, and T-cell lymphoblastic in 1.
  • The initial treatment was chemotherapy in 32 patients (94%); 71% were refractory to initial chemotherapy and 29% developed a relapse after an initial response.
  • [MeSH-major] Lymphoma, Non-Hodgkin / radiotherapy
  • [MeSH-minor] Adult. Aged. Disease Progression. Dose Fractionation. Drug Resistance, Neoplasm. Female. Humans. Male. Middle Aged. Remission Induction. Survivors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16376490.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Saito A, Miyazawa Y, Isoda A, Hatsumi N, Matsumoto M, Kojima M, Sawamura M: [Clinicopathological analysis of patients with angioimmunoblastic T-cell lymphoma (AILT)]. Rinsho Ketsueki; 2008 Feb;49(2):82-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinicopathological analysis of patients with angioimmunoblastic T-cell lymphoma (AILT)].
  • We retrospectively analyzed the clinical course and prognosis of 11 patients with angioimmunoblastic T-cell Lymphoma (AILT).
  • All patients were in clinical stage III or IV.
  • As the initial therapy, 10 patients received combination chemotherapy and only 1 patient received autologous peripheral blood stem cell transplantation.
  • The response rate was 63% and the median survival time was 20 months.
  • The survival time of AILT demonstrated a wide range.
  • [MeSH-major] Immunoblastic Lymphadenopathy / therapy. Lymphoma, T-Cell / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Male. Middle Aged. Peripheral Blood Stem Cell Transplantation. Prognosis. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18341037.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


9. Rodríguez J, Conde E, Gutiérrez A, Arranz R, León A, Marín J, Bendandi M, Albo C, Caballero MD: The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience. Ann Oncol; 2007 Apr;18(4):652-7
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience.
  • BACKGROUND: Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of aggressive lymphomas associated with poor prognosis with standard chemotherapy.
  • Consolidation with autologous stem-cell transplantation (ASCT) may improve survival.
  • We present 74 patients transplanted in first complete response (CR) from the Spanish Lymphoma and Autologous Transplantation Group cooperative group.
  • Eighty-eight percent presented advanced (III-IV) Ann Arbor stage; 53% had B symptoms; 52% had high lactate dehydrogenase; 65% had two or three risk factors of the adjusted-International Prognostic Index; 58% presented a high Tumor score and in 14% more than two adverse factors of the Prognostic Index for peripheral T-cell lymphoma (PIT) were observed.
  • CONCLUSIONS: In a retrospective study with a prolonged follow-up, consolidation with ASCT in CR patients who had presented unfavorable prognostic factors at diagnosis substantially increased the OS and PFS when compared with conventional chemotherapy.
  • Thus, other innovative therapies are still necessary in certain cases.

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17229774.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


10. Yu YX, Shi YK, He XH, Zhou LQ, Zhou SY, Dong M, Feng FY, Sun Y: [Clinical features and treatment outcomes of peripheral T-cell lymphoma, unspecified: a report of 78 cases]. Zhonghua Yi Xue Za Zhi; 2007 Oct 16;87(38):2714-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features and treatment outcomes of peripheral T-cell lymphoma, unspecified: a report of 78 cases].
  • OBJECTIVE: To summarize the clinical features and treatment outcomes of peripheral T-cell lymphoma, unspecified (PTCL-US).
  • METHODS: The medical records of 78 patients with PTCL-US classified according to the revised European and American lymphoma (REAL) or WHO criteria, 58 males and 20 females, aged 39 (9 - 75), 46 of them (59%) being at the stages III/VI and 40 cases (51.2%) with extranodal involvement), treated from Jan 1994 to Dec 2004 in the Cancer Hospital/Institute, Chinese Academy of Medical Sciences, were retrospectively analyzed.
  • 34 cases (43. 7%) were treated with chemoradiotherapy, and 43 (55%) with chemotherapy alone.
  • After the first line treatment the complete recovery (CR) rate and partial recovery (PR) rate were 55.1% (43/78) and 25.6% (20/78) respectively.
  • Achieving CR or PR after first-line treatment, 13 cases received autologous peripheral blood stem cell transplantation (APBSCT).
  • The 5-year OS for the patients treated with first-line APBSCT was 61.5%, not significantly different from that of the patients treated with conventional dose therapy alone (52.3%, P = 0.894).
  • Univariate analysis showed that the factors associated with a worse OS included stage III/IV (P = 0.001), high LDH (P = 0.0001), behavior state score >or= 2 (P = 0.001), and bone marrow involvement (P = 0.011).
  • International prognostic index and prognostic index for peripheral T-cell lymphoma both predicted the overall survival.
  • CONCLUSION: A rare lymphoma with aggressive presentation, PTCL-US responds poorly to conventional treatment.
  • APBSCT is safe and feasible when CR or PR is achieved after first line treatment.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation. Lymphoma, T-Cell, Peripheral / surgery
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Neoplasm Staging. Prognosis. Retrospective Studies. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18167252.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


11. Lee Y, Uhm JE, Lee HY, Park MJ, Kim H, Oh SJ, Jang JH, Kim K, Jung CW, Ahn YC, Park K, Ko YH, Kim WS: Clinical features and prognostic factors of patients with "peripheral T cell lymphoma, unspecified". Ann Hematol; 2009 Feb;88(2):111-9
Genetic Alliance. consumer health - Peripheral T-cell lymphoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features and prognostic factors of patients with "peripheral T cell lymphoma, unspecified".
  • The purpose of this retrospective study was to investigate clinical features and treatment outcomes in patients with peripheral T cell lymphoma-unspecified (PTCL-U).
  • Around 70% of the patients presented with stage III-IV disease; 24% were categorized as high or high-intermediate risk according to the International Prognostic Index (IPI) scoring system, and 45% were classified as groups 3 or 4 using the Prognostic Index for PTCL-U (PIT).
  • Most of the initial chemotherapy regimens were anthracycline-based (75%).
  • The overall response rates for patients treated with initial chemotherapy and salvage chemotherapy were 63.1% (52.6% of complete response (CR), 10.5% of partial response (PR)) and 35% (9% of CR, 26%of PR), respectively.
  • [MeSH-major] Lymphoma, T-Cell, Peripheral / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Disease Progression. Female. Humans. Infant. Male. Middle Aged. Positron-Emission Tomography. Prognosis. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18648812.001).
  • [ISSN] 1432-0584
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


12. Milani C, Castillo J: HIV-associated peripheral T-cell lymphoma. J Clin Oncol; 2009 May 20;27(15_suppl):e19551

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] HIV-associated peripheral T-cell lymphoma.
  • : e19551 Background: T-cell lymphomas (TCL) constitute 3% of all AIDS-related lymphomas.
  • These lymphomas comprise a diverse group of disease entities, including peripheral T-cell lymphomas (PTCL), which represent the most common subtype.
  • Data regarding patient age, gender, HIV status (CD4 count, viral load, opportunistic infections), use of HAART, lymphoma features (B symptoms, stage, sites of involvement, immunophenotype, molecular studies), EBV coinfection, therapy, and outcome (survival, cause of death) were analyzed and reported descriptively.
  • Seventeen patients (50%) had an opportunistic infection, but only 7 patients (26%) were on HAART treatment; 4 patients on HAART (57%) were alive at time of publication.
  • Stage III and IV disease was found in 17 and 5 cases, respectively, accounting for 76% of the total cases.
  • T-cell receptor gene rearrangement was positive in 10 out of 10 (100%) analyzed cases.
  • Therapy for PTCL was administered in 23 cases (68%), while 10 cases (30%) did not receive therapy; 9 of the treated patients (39%) received CHOP with a 33% remission rate.
  • Twenty-two patients (69%) died complicated by infections in 57% and lymphoma progression in 36% of cases.
  • Apart from marked immunosuppression, the poor prognosis of HIV-associated PTCL appears to be related to advanced stage at presentation, presence of B symptoms, elevated LDH levels, prominent extranodal disease, and poor response to CHOP chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 27961094.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


13. Milpied NJ, Lamy T, Casassus P, Deconninck E, Gressin R, Le Maignan C, Tournilhac O, Dugay J, Legouffe E, Delwail V: Front-line high-dose chemotherapy (HDT) combined with rituximab for adults with aggressive large B cell lymphoma (DLBCL). A pilot study by the GOELAMS. J Clin Oncol; 2004 Jul 15;22(14_suppl):6662

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Front-line high-dose chemotherapy (HDT) combined with rituximab for adults with aggressive large B cell lymphoma (DLBCL). A pilot study by the GOELAMS.
  • We have shown that HDT with autologous stem cell transplantation is superior to CHOP in young adults with DLCL (Milpied et al NEJM in press).
  • This program consisted of 2 courses of high-dose CHOP-like regimen, 15 days apart, with rituximab (375 mg/ m2) on d1 of each course, followed by rituximab on d 22, harvest of peripheral blood stem cells (G-CSF mobilized) on days 28,29, then rituximab on d 36 followed by a course of high-dose methotrexate with cytarabine and by a BEAM regimen starting on d 66 to 80, followed by the infusion of stem cells.
  • Their median age was 50y.o.( 18-60 yo); 23 had WHO PS >/= 2, the LDH level was > N in 37 patients and 38 had Ann Arbor stage III or IV.
  • The age-adjusted IPI was intermediate-high in 21 and high in 19 patients.At the time of this abstract, the program has been completed in 75% of the patients.
  • Three patients died of toxicity of the treatment before the BEAM regimen and autologous transplantation.
  • On an intent-to-treat basis, the response rate at the end of the treatment was CR/CRu= 64%, PR=8%, failure to achieve a response or progression= 20% and toxic death=8%.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28016375.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Rao RA, Chin K, Pilichowska M, Foss F: Outcomes in peripheral T-cell lymphoma: Prognosis based on IPI staging. J Clin Oncol; 2004 Jul 15;22(14_suppl):6706

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcomes in peripheral T-cell lymphoma: Prognosis based on IPI staging.
  • : 6706 Background: The T cell non-Hodgkin's lymphomas comprise a heterogeneous group of diseases which, with the exception of anaplastic large cell lymphoma, are associated with short response durations and survival after conventional cytotoxic chemotherapy .
  • Recently, a retrospective review by the Non-Hodgkin's Lymphoma Classification Project demonstrated that survival and failure-free survival were correlated with performance status and the International Prognostic Index (IPI).
  • METHODS: We performed a retrospective analysis of 35 patients (m=20, f=15) with non-cutaneous T-cell lymphoma treated at a single institution to determine whether clinical features or IPI classification were predictive of outcome.
  • The histopathologic subtypes included: AILD (5), NK-T cell lymphoma (2), PTCLu (14), HTLV-1 associated ATL (3), T-CLL (6), T-ALL (5).
  • The majority of patients had advanced disease (31 stage IV, 3 Stage III) at presentation.
  • The majority of patients (68%) were treated with anthracycline based multi-agent chemotherapy.
  • Further multi-institutional studies are warranted to further explore the predictors of outcome in underrepresented histologic subtypes of T-cell NHL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014609.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


15. d'Amore F, Radford J, Relander T, Jerkeman M, Tilly H, Osterborg A, Morschhauser F, Gramatzki M, Dreyling M, Bang B, Hagberg H: Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma. Br J Haematol; 2010 Sep;150(5):565-73
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of zanolimumab (HuMax-CD4) in relapsed or refractory non-cutaneous peripheral T cell lymphoma.
  • The efficacy and safety of zanolimumab (HuMax-CD4) in patients with relapsed or refractory peripheral T Cell lymphoma (PTCL) was evaluated.
  • Twenty-one adult patients with relapsed or refractory CD4(+) PTCL of non-cutaneous type (angioimmunoblastic T cell lymphoma (AITL) n = 9, PTCL-not otherwise specified (NOS) n = 7, anaplastic large cell lymphoma (ALCL) n = 4 and enteropathy type T cell lymphoma n = 1) were treated in a single-arm multi-centre study, with weekly intravenous infusions of zanolimumab 980 mg for 12 weeks.
  • Seventeen of the patients had advanced stage disease (Ann Arbor stages III-IV).
  • Responses were obtained in different PTCL entities: AITL (n = 3), ALCL (n = 1) and PTCL-NOS (n = 1).
  • In general, the trial drug was well tolerated with no major toxicity.
  • Zanolimumab at a dose of 980 mg weekly demonstrated clinical activity and an acceptable safety profile in this poor-prognosis patient population, suggesting that the potential benefit combining zanolimumab with standard chemotherapy in the treatment of PTCL should be investigated.
  • [MeSH-major] Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Lymphoma, T-Cell, Peripheral / drug therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Humans. Infusions, Intravenous. Male. Middle Aged. Opportunistic Infections / chemically induced. Prospective Studies. Recurrence. Treatment Outcome

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20629661.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / zanolimumab
  •  go-up   go-down


16. Zinzani PL, Venturini F, Stefoni V, Fina M, Pellegrini C, Derenzini E, Gandolfi L, Broccoli A, Argnani L, Quirini F, Pileri S, Baccarani M: Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome. Ann Oncol; 2010 Apr;21(4):860-3
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gemcitabine as single agent in pretreated T-cell lymphoma patients: evaluation of the long-term outcome.
  • BACKGROUND: Peripheral T-cell lymphoma unspecified (PTCLU) and mycosis fungoides (MF) often show resistance to conventional chemotherapy.
  • We report the long-term update of 39 pretreated T-cell lymphoma patients treated with gemcitabine.
  • All patients with MF had a T3-T4, N0, and M0 disease and patients with PTCLU had stage III-IV disease.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19887465.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


17. Coffey J, Hodgson DC, Gospodarowicz MK: Therapy of non-Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging; 2003 Jun;30 Suppl 1:S28-36
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy of non-Hodgkin's lymphoma.
  • The WHO classification of hematopoietic and lymphoid tumours classifies lymphomas into B-cell and T-cell neoplasms.
  • B-cell lymphomas account for more than 85% of all lymphomas.
  • The two most common histologic disease entities are follicular lymphomas and diffuse large B-cell lymphomas.
  • Radiation therapy is used for stage I and II disease, while alkylating agent chemotherapy, immunotherapy and radioimmunotherapy are most frequently used in stage III and IV disease that requires treatment.
  • Most patients with follicular lymphoma enjoy prolonged survival, but at present there is no evidence that those with stage III and IV follicular lymphoma can be cured.
  • Diffuse large B-cell lymphomas serve as a paradigm for treating aggressive lymphomas.
  • Stage I and II diffuse large cell lymphomas are generally treated with combined modality therapy with doxorubicin-based chemotherapy followed by involved field radiation therapy, while those with stage III and IV disease are treated with chemotherapy alone.
  • Patients who fail initial management are treated with further chemotherapy.
  • High-dose chemotherapy with stem cell rescue has been shown to be particularly effective as salvage treatment for diffuse large cell lymphomas.
  • The management of a heterogeneous group of primary extranodal lymphomas in general follows the above treatment principles, with additional treatment being required for those with a high risk of CNS failures, or involvement of contralateral paired organs.
  • The management of MALT lymphomas, especially gastric MALT lymphoma, deserves special attention because of the high response rate to Helicobacter pylori eradication therapy.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Combined Modality Therapy. Female. Humans. Immunotherapy. Male. Neoplasm Staging. Peripheral Blood Stem Cell Transplantation. Radioimmunotherapy. Transplantation, Autologous

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] Ann Oncol. 2002 Sep;13(9):1341-6 [12196358.001]
  • [Cites] Important Adv Oncol. 1994;:117-29 [8206485.001]
  • [Cites] N Engl J Med. 1993 Nov 25;329(22):1608-14 [8232429.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Br J Cancer. 2001 Jul 6;85(1):29-35 [11437398.001]
  • [Cites] J Clin Oncol. 2002 Oct 1;20(19):4022-31 [12351600.001]
  • [Cites] J Clin Oncol. 2000 May;18(10 ):2010-6 [10811664.001]
  • [Cites] Br J Cancer. 1993 Apr;67(4):792-7 [8471438.001]
  • [Cites] N Engl J Med. 1995 Dec 7;333(23):1540-5 [7477169.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 6;93(11):824-42 [11390532.001]
  • [Cites] J Clin Oncol. 2002 May 15;20(10 ):2453-63 [12011122.001]
  • [Cites] Blood. 1994 Sep 1;84(5):1361-92 [8068936.001]
  • [Cites] Leuk Lymphoma. 1992 May;7(1-2):135-8 [1472924.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Aug 1;50(5):1258-64 [11483337.001]
  • [Cites] J Clin Oncol. 2002 Aug 15;20(16):3545-57 [12177115.001]
  • [Cites] Lancet. 1993 Dec 18-25;342(8886-8887):1514-6 [7902900.001]
  • [Cites] Gut. 2002 May;50 Suppl 3:III19-24 [11953328.001]
  • [Cites] J Clin Oncol. 1999 Jan;17(1):268-76 [10458242.001]
  • [Cites] Radiother Oncol. 1995 Sep;36(3):167-71 [8532901.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1337-49 [12128137.001]
  • [Cites] Ann Oncol. 2002 Sep;13(9):1347-55 [12196359.001]
  • [Cites] Eur J Cancer. 2001 Sep;37(13):1659-67 [11527693.001]
  • [Cites] J Clin Oncol. 2000 Mar;18(5):947-55 [10694543.001]
  • [Cites] N Engl J Med. 1998 Jul 2;339(1):21-6 [9647875.001]
  • [Cites] Cancer. 1982 May 15;49(10):2112-35 [6896167.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Mar 1;52(3):643-51 [11849785.001]
  • [Cites] J Clin Oncol. 1996 Apr;14(4):1282-90 [8648385.001]
  • [Cites] Lancet. 1993 Sep 4;342(8871):575-7 [8102719.001]
  • [Cites] Ann Hematol. 2001;80 Suppl 3:B66-72 [11757712.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):280-2 [11807154.001]
  • [Cites] N Engl J Med. 2002 Jul 11;347(2):89-94 [12110736.001]
  • [Cites] Lancet. 2001 Jan 6;357(9249):39-40 [11197361.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2001 Jul 1;50(3):743-9 [11395243.001]
  • [Cites] Blood. 1994 Jun 15;83(12):3800-7 [8204898.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2780-95 [9704731.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2817-24 [9704734.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] Int J Cancer. 1997 Nov 27;73(5):645-50 [9398040.001]
  • [Cites] J Clin Oncol. 1998 Aug;16(8):2825-33 [9704735.001]
  • [Cites] J Natl Cancer Inst. 2000 Aug 2;92(15):1240-51 [10922409.001]
  • [Cites] Cancer. 1983 Oct 15;52(8):1410-6 [6193858.001]
  • [Cites] Cancer. 2002 Apr 1;94(7):2015-23 [11932904.001]
  • [Cites] Blood. 2000 Feb 1;95(3):802-6 [10648389.001]
  • (PMID = 12692688.001).
  • [ISSN] 1619-7070
  • [Journal-full-title] European journal of nuclear medicine and molecular imaging
  • [ISO-abbreviation] Eur. J. Nucl. Med. Mol. Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 54
  •  go-up   go-down


18. Lin HN, Liu CY, Hong YC, Pai JT, Yang CF, Yu YB, Hsiao LT, Chiou TJ, Liu JH, Gau JP, Tzeng CH, Chen PM: Clinical features and prognostic factors of angioimmunoblastic T-cell lymphoma in Taiwan: a single-institution experience. Leuk Lymphoma; 2010 Dec;51(12):2208-14
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical features and prognostic factors of angioimmunoblastic T-cell lymphoma in Taiwan: a single-institution experience.
  • Angioimmunoblastic T-cell lymphoma (AITL) is a rare subtype of peripheral T-cell lymphoma that carries a poor prognosis.
  • Among all patients, 67.7% were Ann Arbor stage III or IV, 58.1% presented with B symptoms, 48.4% had hypoalbuminenia (<35 g/L), and 63.3% had elevated lactate dehydrogenase (LDH) at diagnosis.
  • First-line chemotherapy was mostly CHOP (cyclophosphamide, vincristine, doxorubicin, and prednisolone)-based and complete response (CR) was achieved in 25% of patients.
  • In multivariate analysis, initial presentation with fever (p = 0.035), advanced stage (p = 0.024), and failure to achieve CR (p = 0.029) were independent adverse factors associated with poorer OS.
  • Interestingly, OS did not differ whether chemotherapy regimens contained anthracycline or not.
  • Despite the prognosis being generally poor, patients with AITL should be treated with the goal of achieving CR, regardless of anthracycline- or non-anthracycline-based chemotherapy.
  • [MeSH-major] Immunoblastic Lymphadenopathy / diagnosis. Immunoblastic Lymphadenopathy / pathology. Lymphoma, T-Cell / diagnosis. Lymphoma, T-Cell / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Risk Factors. Survival Analysis. Taiwan / epidemiology. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2011 Jan;52(1):1-2 [21133725.001]
  • (PMID = 21054150.001).
  • [ISSN] 1029-2403
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


19. Huang HQ, Lin XB, Pan ZH, Bu Q, Gao Y, Wang BF, Cai QQ, Xia ZJ, Xu RH, Jiang WQ, Guan ZZ: [CEOP regimen in the treatment for non-Hodgkin's lymphoma]. Zhonghua Zhong Liu Za Zhi; 2007 May;29(5):391-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [CEOP regimen in the treatment for non-Hodgkin's lymphoma].
  • OBJECTIVE: The aim of this study is to analyse the efficacy and toxicity of CEOP regimen in the treatment of non-Hodgkin's lymphoma (NHL).
  • RESULTS: Of these 121 patients, 83 (68.6%) had B-cell NHL and 38(31.4%) peripheral T or NK-cell NHL; 55.
  • 4% (67/121) had early disease (stage I or II), and 89.3% (108/121) had IPI score 0-2.
  • The overall response (OR) rate in this series was 90.9% (110/121) with a complete remission (CR) rate of 71.9% (87/121); whereas the response rate of chemotherapy alone was 88.4% (107/121) with a CR rate of 67.8% (82/121).
  • Major toxicity consisted of grade III-IV myelosuppression (11.9%), neutropenia (1.9%) and thrombocytopenia and anemia (1.1%).
  • The overall 1-, 3- and 5-year survival rate was 84.8%, 62.7% and 55.9%, respectively, with a median survival time of 85 months (2-118 months).
  • CONCLUSION: Our data show that CEOP regimen combined with or without radiotherapy for the involved field is effective and well tolerated by the patients with non-Hodgkin's lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Alopecia / chemically induced. Child. Combined Modality Therapy. Cyclophosphamide / adverse effects. Cyclophosphamide / therapeutic use. Epirubicin / adverse effects. Epirubicin / therapeutic use. Female. Follow-Up Studies. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / radiotherapy. Male. Middle Aged. Neoplasm Staging. Neutropenia / chemically induced. Prednisone / adverse effects. Prednisone / therapeutic use. Remission Induction. Retrospective Studies. Survival Analysis. Thrombocytopenia / chemically induced. Vincristine / adverse effects. Vincristine / therapeutic use

  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17892140.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CEOP protocol 1
  •  go-up   go-down


20. Küpeli S, Varan A, Demir H, Aydin B, Yüce A, Büyükpamukçu M: Association of Helicobacter pylori and childhood lymphoma. J Pediatr Hematol Oncol; 2007 May;29(5):301-4
MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Association of Helicobacter pylori and childhood lymphoma.
  • We aimed to estimate the frequency of association between non-Hodgkin lymphoma (NHL) with abdominal, gastric, or intestinal involvement and Helicobacter pylori in childhood.
  • Patients who were given chemotherapy previously or who received H. pylori eradication therapy were excluded from the study.
  • Six had stage IV characteristics, whereas another 9 patients had stage III disease.
  • Ten had high-grade B-cell lymphoma.
  • First patient had T-cell lymphoma and stage IV disease with involvement in stomach, mediastinum, peripheral lymph nodes, and bone marrow.
  • The second one had anaplastic large cell lymphoma exclusively in abdominal lymph nodes.
  • Last patient had Burkitt lymphoma and stage IV disease, with primary tumor localization in abdominal lymph nodes, liver, and kidneys.
  • [MeSH-major] Gastrointestinal Neoplasms / epidemiology. Helicobacter Infections / epidemiology. Helicobacter pylori / isolation & purification. Lymphoma, B-Cell / epidemiology. Lymphoma, Non-Hodgkin / epidemiology
  • [MeSH-minor] Adolescent. Anti-Bacterial Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Combined Modality Therapy. Drug Therapy, Combination. Female. Humans. Male. Neoplasm Staging. Prospective Studies. Recurrence. Risk Assessment. Sampling Studies. Treatment Outcome. Turkey / epidemiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17483706.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  •  go-up   go-down


21. Huang HQ, Peng YL, Cai QQ, Lin XB, Li YH, Xia ZJ, Lin TY, Sun XF, Zhang L, Xu GC, He YJ, Jiang WQ, Guan ZZ: [Long-term outcomes of 392 non-Hodgkin's lymphoma patients treated with pirarubicin based regimens]. Zhonghua Xue Ye Xue Za Zhi; 2005 Oct;26(10):577-80
Hazardous Substances Data Bank. DOXORUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Long-term outcomes of 392 non-Hodgkin's lymphoma patients treated with pirarubicin based regimens].
  • OBJECTIVE: To analyse the effectiveness and toxicity of combined chemotherapy regimen containing pirarubicin (THP) in the treatment of non-Hodgkin's lymphoma (NHL).
  • B-cell and T/NK cell NHL accounted for 68.4% and 23.2% respectively with 56.9% of diffuse large B cell lymphoma and 12.5% of peripheral T cell lymphoma.
  • 92.6% of the patients were ECOG < 1, 63.2% in stage I + II, 84.7% with IPI score 0 - 2 and 25% with B symptoms, 93.9% (368/392) of the patients received CTOP (containing THP) regimen chemotherapy and among them 28.5% (112/392) plus involved field radiotherapy.
  • The overall response rate was 88.5% (341/385) with a complete remission (CR) rate of 63.6%, major toxicity was myelosuppression with 12.8%, 1.0% and 1.5% of grade III - IV neutropenia, thrombocytopenia and anemia, respectively.
  • Treatment-related mortality was 1.6% (6/368).
  • Median survival time has not been achieved.
  • CONCLUSION: The efficacy of THP based regimen CTOP for the treatment of aggressive NHL is promising.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Doxorubicin / analogs & derivatives. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16532963.001).
  • [ISSN] 0253-2727
  • [Journal-full-title] Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
  • [ISO-abbreviation] Zhonghua Xue Ye Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 80168379AG / Doxorubicin; D58G680W0G / pirarubicin
  •  go-up   go-down


22. El Weshi A, Akhtar S, Mourad WA, Ajarim D, Abdelsalm M, Khafaga Y, Bazarbashi S, Maghfoor I: T-cell/histiocyte-rich B-cell lymphoma: Clinical presentation, management and prognostic factors: report on 61 patients and review of literature. Leuk Lymphoma; 2007 Sep;48(9):1764-73
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell/histiocyte-rich B-cell lymphoma: Clinical presentation, management and prognostic factors: report on 61 patients and review of literature.
  • T-cell/histiocyte-rich B-cell lymphoma (TC/HRBCL) is a rare subtype of diffuse large B-cell non-Hodgkin's lymphoma (DLBCL) with characteristic morphologic and immunophenotypic features, often misdiagnosed as Hodgkin's lymphoma and peripheral T-cell lymphoma.
  • Few and conflicting clinical data are available in the literature addressing optimal treatment, prognosis and outcome.
  • We retrospectively reviewed all patients diagnosed and managed at our institution between 1995 and 2004 diagnosed with T-cell-rich-B-cell lymphoma by WHO criteria.
  • Stage distribution was I - II in 21 patients, and III - IV in 40.
  • All 59 newly diagnosed TC/HRBCL patients were treated with CHOP or R-CHOP combination chemotherapy +/- radiation therapy.
  • The overall response rate was 85% and nine patients progressed on therapy.
  • Fourteen patients relapsed with a median time of relapse of 6 months (range, 2 - 28).
  • It has an aggressive course and poor outcome; with most of patients presenting with advanced disease stage together with high IPI score.
  • Treatment outcome seems to be similar to IPI matched DLBCL counterpart.
  • [MeSH-major] Lymphoma, B-Cell / drug therapy. Lymphoma, Large B-Cell, Diffuse / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prognosis. Salvage Therapy. Treatment Failure

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Leuk Lymphoma. 2007 Sep;48(9):1670-1 [17786700.001]
  • (PMID = 17786712.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 31
  •  go-up   go-down


23. Koizumi K, Minauchi K, Odani T, Kondo M, Takada A, Mukai M: [ALK-negative primary gastric anaplastic large cell lymphoma]. Rinsho Ketsueki; 2007 May;48(5):397-401
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [ALK-negative primary gastric anaplastic large cell lymphoma].
  • Gastroendoscopy revealed a Borrmann III type tumor which was diagnosed from the biopsied specimen as an anaplastic large cell lymphoma (ALCL).
  • CT scan revealed para-aortic and left-supra clavicular lymph node swelling, so her clinical stage was defined as IIIE according to the Ann Arbor classification.
  • The patient first of all received CHOP therapy, however her lymphoma lesions increased in size.
  • Therefore she underwent salvage chemotherapy regimens and autologous peripheral blood stem cell transplantation (APBSCT).
  • [MeSH-major] Biomarkers, Tumor / analysis. Lymphoma, Large B-Cell, Diffuse / therapy. Protein-Tyrosine Kinases / analysis. Stomach Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cisplatin / administration & dosage. Combined Modality Therapy. Epirubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Middle Aged. Peripheral Blood Stem Cell Transplantation. Receptor Protein-Tyrosine Kinases. Remission Induction. Salvage Therapy. Transplantation, Autologous

  • Genetic Alliance. consumer health - Gastric Lymphoma.
  • Genetic Alliance. consumer health - Anaplastic Large Cell Lymphoma.
  • Genetic Alliance. consumer health - Lymphoma, large-cell.
  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17571585.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 3Z8479ZZ5X / Epirubicin; 6PLQ3CP4P3 / Etoposide; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; VIP-E protocol
  • [Number-of-references] 15
  •  go-up   go-down


24. Chen YC, Ho CL, Kao WY, Hwang JM, Sheu LF, Chao TY: Adult lymphoblastic lymphoma in Taiwan: an analysis of treatment results of 26 patients. Ann Hematol; 2001 Nov;80(11):647-52
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult lymphoblastic lymphoma in Taiwan: an analysis of treatment results of 26 patients.
  • Lymphoblastic lymphoma (LBL) frequently affects young adults and usually presents with a mediastinal mass as well as bone marrow involvement.
  • Although the frequency of LBL in the Far East is higher than that of Western countries, no reports regarding treatment of this disease have as yet been reported.
  • We herein report our treatment experience and verify the efficacy of the Stanford/Northern California Oncology Group (NCOG) protocol for this disease and recommend treatment strategies for LBL patients.
  • Nineteen patients had an initial stage IV disease.
  • Of the 23 cases in which immunological studies were performed, 20 proved to be of T cell lineage, 1 of B cell type, and the other 2 lacked both T and B markers.
  • One patient was excluded for analysis because of initial treatment by surgery.
  • Five patients with stage II-III diseases achieved long-term disease-free survival of 11-36 months with the Stanford/NCOG protocol with a median follow-up of 24 months.
  • Four patients in late stage or relapse received allogeneic bone marrow transplantation (BMT).
  • Two other patients in CR were treated with high-dose chemotherapy (HDCT) supported with autologous BMT and peripheral blood stem cell transplantation (PBSCT), respectively.
  • B symptoms and treatment without the Stanford/NCOG protocol were found to have significantly negative impacts on both patients' overall and progression-free survivals.
  • Our results suggest that the Stanford/NCOG protocol may be an effective chemotherapy for adult LBL and may provide long-term remission for patients in an early stage of disease.
  • For those patients with LBL in an advanced stage or in relapse, HDCT with allogeneic or autologous BMT is probably the treatment of choice.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asparaginase / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Prednisolone / administration & dosage. Vincristine / administration & dosage
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Marrow Transplantation. Etoposide / administration & dosage. Female. Hematopoietic Stem Cell Transplantation. Humans. Male. Mechlorethamine / administration & dosage. Methotrexate / administration & dosage. Middle Aged. Prednisone / administration & dosage. Procarbazine / administration & dosage. Prognosis. Recurrence. Retrospective Studies. Survival Analysis. Taiwan. Treatment Outcome

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. NITROGEN MUSTARD N-OXIDE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. MECHLORETHAMINE HYDROCHLORIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. PROCARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11757723.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 35S93Y190K / Procarbazine; 50D9XSG0VR / Mechlorethamine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 9PHQ9Y1OLM / Prednisolone; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CHOP protocol; ProMACE-MOPP protocol; Stanford-NCOG protocol
  •  go-up   go-down


25. Chen SW, Chang ST, Lu CL, Hwang WS, Tsao CJ, Huang WT, Chang KY, Chuang SS: Upper aerodigestive tract lymphoma in Taiwan. J Clin Pathol; 2010 Oct;63(10):888-93
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upper aerodigestive tract lymphoma in Taiwan.
  • AIM: To better understand the spectrum of primary lymphomas in the upper aerodigestive tract, a common site of extranodal lymphoma.
  • MATERIALS AND METHODS: Lymphoma cases diagnosed at an institution in southern Taiwan from 1992 to 2007 were retrospectively studied with pathology and history review, immunohistochemistry, in situ hybridisation for Epstein-Barr virus (EBER-ISH), and statistical analysis.
  • Phenotypically, there were 45 (64%) B cell and 25 (36%) T cell or extranodal natural killer (NK)/T cell lymphoma (ENKL) including 42 (60%) diffuse large B cell lymphomas (DLBCLs), 22 (31%) ENKLs, three unspecified peripheral T cell lymphomas, two follicular lymphomas and one Burkitt lymphoma.
  • Most patients received chemotherapy with or without radiotherapy.
  • The 5-year overall survival for all patients was 56.3% with B and T or NK/T cell lymphomas at 66.0% and 40.6%, respectively.
  • Univariate analysis revealed that sinonasal presentation, T or NK/T cell phenotype, raised lactate dehydrogenase (LDH) activity, and Ann Arbor stage III/IV diseases were associated with prognostically significant higher hazard ratio (HR) of lymphoma-related death.
  • CONCLUSIONS: Only a limited number of lymphoma entities occurred primarily in this anatomical region.
  • [MeSH-major] Head and Neck Neoplasms / pathology. Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / blood. Child. Epidemiologic Methods. Epstein-Barr Virus Infections / complications. Female. Humans. L-Lactate Dehydrogenase / blood. Lymphoma, B-Cell / pathology. Lymphoma, B-Cell / therapy. Lymphoma, B-Cell / virology. Lymphoma, T-Cell / pathology. Lymphoma, T-Cell / therapy. Lymphoma, T-Cell / virology. Male. Middle Aged. Mouth Neoplasms / pathology. Mouth Neoplasms / therapy. Mouth Neoplasms / virology. Neoplasm Staging. Prognosis. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20876320.001).
  • [ISSN] 1472-4146
  • [Journal-full-title] Journal of clinical pathology
  • [ISO-abbreviation] J. Clin. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


26. Sun XF, Zhen ZJ, Xiang XJ, Ling JY, Peng RJ, Xia Y, Zheng L, Luo WB, Lin H, Guan ZZ: [Efficacy of modified B-NHL-BFM-90 protocol on anaplastic T-cell lymphoma in children and adolescents]. Ai Zheng; 2009 May;28(5):506-10
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of modified B-NHL-BFM-90 protocol on anaplastic T-cell lymphoma in children and adolescents].
  • BACKGROUND AND OBJECTIVE: Anaplastic T-cell lymphoma in children and adolescents is an aggressive malignant non-Hodgkin's lymphoma (NHL).
  • The optimal treatment regimen needs to be investigated.
  • This study was to evaluate the efficacy of modified B-NHL-BFM-90 protocol on anaplastic T-cell lymphoma in children and adolescents.
  • METHODS: From October 2002 to January 2008, 18 untreated anaplastic T-cell lymphoma patients aged less than 16 years were enrolled, and treated with modified B-NHL-BFM-90 protocol including cyclophosphamide, vincristine, ifosfamide, etoposide, adriamycin, HD-methotrexate, vindesine, dexamethasone, cytarabine/HD-cytarabine.
  • The 3-year event-free survival (EFS) rates were (87.4+/-8.4)% for all patients, 100% for stage II patients, and (85.1+/-9.7)% for stage III/IV patients; 100% for low risk group, (88.9+/-10.5)% for moderate risk group, and (80.0+/-17.9)% for high risk group.
  • One patient with stage IV disease received autologous peripheral blood stem cell transplantation (PBSCT) after CR and was still alive.
  • Two patients had tumor relapsed and died at three and five months after off treatment, respectively.
  • CONCLUSIONS: Modified B-NHL-BFM-90 protocol, with tolerable toxicity, is an effective treatment regimen for anaplastic T-cell lymphoma in children and adolescents.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Large-Cell, Anaplastic / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. L-Lactate Dehydrogenase / blood. Leukopenia / chemically induced. Male. Methotrexate / administration & dosage. Neoplasm Staging. Remission Induction. Stem Cell Transplantation. Thrombocytopenia / chemically induced. Vincristine / administration & dosage. Vindesine / administration & dosage

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINDESINE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19624879.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; EC 1.1.1.27 / L-Lactate Dehydrogenase; RSA8KO39WH / Vindesine; UM20QQM95Y / Ifosfamide; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


27. Tang YJ, Tang JY, Pan C, Xue HL, Chen J, Shen SH, Dong L, Zhou M, Wang YP, Gu LJ, Jiang H, Ye QD: [Clinical characteristics and treatment outcome of 36 cases with non-Hodgkin's lymphoma arising from mediastinum in children]. Zhonghua Er Ke Za Zhi; 2009 Sep;47(9):687-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics and treatment outcome of 36 cases with non-Hodgkin's lymphoma arising from mediastinum in children].
  • OBJECTIVE: Non-Hodgkin's lymphoma (NHL) presenting as mediastinal mass is usually progressive and may cause severe respiratory distress and death.
  • Their clinical characteristics, pathologic classification, diagnosis, outcome of different treatment protocol were retrospectively analyzed.
  • Diagnosis was established on pathology that was achieved by mediastinal mass or peripheral lymph nodes biopsy, while some were diagnosed based on bone marrow or pleural effusion cytology study and immunophenotyping.
  • Patients who experienced superior vena cava syndrome (SVCS) and/or superior mediastinum syndrome (SMS) received induction chemotherapy with cyclophosphamide (C), vincristine (O) and prednisone (P) for one week.
  • RESULTS: Twenty-seven cases experienced mediastinal mass or peripheral lympho nodes biopsy and were diagnosed by histopathology and immunohistochemistry.
  • Of them, 24 were lymphoblastic lymphoma and 3 were anaplastic large cell lymphoma.
  • All the 36 cases were T-cell type.
  • Twenty-four cases were in stage III, 12 in stage IV.
  • Twenty-four patients had urgent situation of SVCS and airway obstruction, 22 patients reached good response after emergency management including COP induction chemotherapy and pleural effusion suction.
  • Thirteen patients died from disease progression, relapse or severe infection during chemotherapy.
  • Induction chemotherapy for emergency situation was efficacious.
  • [MeSH-major] Lymphoma, Non-Hodgkin. Mediastinal Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021793.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


28. Simon A, Peoch M, Casassus P, Deconinck E, Colombat P, Desablens B, Tournilhac O, Eghbali H, Foussard C, Jaubert J, Vilque JP, Rossi JF, Lucas V, Delwail V, Thyss A, Maloisel F, Milpied N, le Gouill S, Lamy T, Gressin R: Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95. Br J Haematol; 2010 Oct;151(2):159-66
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Upfront VIP-reinforced-ABVD (VIP-rABVD) is not superior to CHOP/21 in newly diagnosed peripheral T cell lymphoma. Results of the randomized phase III trial GOELAMS-LTP95.
  • Peripheral T-Cell lymphomas (PTCL) are relatively rare diseases but appear to be highly aggressive and display worse remission and survival rates than B-cell lymphomas.
  • Despite unsatisfactory results with the cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) regimen, it remains the reference front-line therapy in these diseases, but has not been challenged in phase III trials.
  • The Groupe Ouest Est d'Etude des Leucémies et Autres Maladies du Sang (GOELAMS) devised an alternative therapeutic schedule including etoposide, ifosfamide, cisplatin alternating with doxorubicin, bleomycin, vinblastine, dacarbazine (VIP-reinforced-ABVD; VIP-rABVD) and compared it to CHOP/21 as front-line treatment in non-cutaneous PTCL.
  • Anaplastic large cell lymphoma type and Ann Arbor stage I-II were identified as two independent favourable prognostic factors influencing survival.
  • VIP-rABVD was not superior to CHOP/21 in terms of EFS as first-line treatment of PTCL, confirming that CHOP/21 remains the reference regimen in these lymphomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell, Peripheral / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bleomycin / administration & dosage. Bleomycin / adverse effects. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Dacarbazine / administration & dosage. Dacarbazine / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Etoposide / administration & dosage. Etoposide / adverse effects. Female. Humans. Ifosfamide / administration & dosage. Ifosfamide / adverse effects. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Prednisone / adverse effects. Survival Analysis. Treatment Outcome. Vinblastine / administration & dosage. Vinblastine / adverse effects. Vincristine / administration & dosage. Vincristine / adverse effects. Young Adult

  • Genetic Alliance. consumer health - Peripheral T-cell lymphoma.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. VINBLASTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 Blackwell Publishing Ltd.
  • (PMID = 20738307.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; 5J49Q6B70F / Vincristine; 5V9KLZ54CY / Vinblastine; 6PLQ3CP4P3 / Etoposide; 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide; VB0R961HZT / Prednisone; ABVD protocol; CHOP protocol; ICE protocol 1
  •  go-up   go-down


29. Qin Y, Shi YK, He XH, Yang JL, Yang S, Yu YX, Li B, Wang QL, Zhou LQ, Sun Y: [Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil]. Ai Zheng; 2006 Apr;25(4):481-5
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil].
  • BACKGROUND & OBJECTIVE: Head and neck lymphoma develops predominantly in the tonsil.
  • This study was to investigate the clinical features of primary non-Hodgkin's lymphoma (NHL) of the tonsil, and to explore possible ways to improve the prognosis and quality of life of the patients after treatment.
  • Stage I-II patients received radiochemotherapy-predominant treatment, whereas stage III-IV patients received chemotherapy-predominant treatment.
  • RESULTS: Of the 89 cases, 60 (67%) were diffuse large B-cell subtype, 11 (12%) were peripheral T-cell subtype, 5 (6%) were indolent lymphoma, 1 was anaplastic large T-cell lymphoma, and 1 was T lymphoblastic lymphoma; 81 (91%) were stage I-II disease.
  • Of the 89 patients, 58 (72%) received radiochemotherapy, 19 (21%) received radiotherapy alone, 3 received chemotherapy alone, and 1 received radiochemotherapy combined with rituximab.
  • The 5-year overall survival rate was 80%, that of stage I-II patients was 84%.
  • Diffuse large B-cell lymphoma is the most common pathologic subtype.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin. Tonsillar Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Drug Resistance, Neoplasm. Female. Follow-Up Studies. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Lymphoma, T-Cell, Peripheral / drug therapy. Lymphoma, T-Cell, Peripheral / pathology. Lymphoma, T-Cell, Peripheral / radiotherapy. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prednisone / therapeutic use. Quality of Life. Retrospective Studies. Survival Rate. Vincristine / therapeutic use. Young Adult

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613685.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


30. Kutluk T, Varan A, Akyüz C, Büyükpamukçu M: Clinical characteristics and treatment results of LMB/LMT regimen in children with non-Hodgkin's lymphoma. Cancer Invest; 2002;20(5-6):626-33
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and treatment results of LMB/LMT regimen in children with non-Hodgkin's lymphoma.
  • Ninety-seven patients with newly diagnosed, untreated non-Hodgkin's lymphoma, between April 1994 and December 1997, were included in this study.
  • Modified lymphoma malign B (LMB) and lymphoma malign T (LMT) regimens were used for treatment of B- and T-cell disease, respectively.
  • Ten (10.3%), 68 (70.1%), and 19 (19.6%) patients had stage II, III, and IV disease, respectively.
  • Forty-eight, 19, 15, 9, 5, and 1 patients had tumors at abdominal, mediastinal, disseminated, head and neck, extranodal, and peripheral nodal locations, respectively.
  • Two-year overall survival rates were 90, 66.1, and 50.8% for patients with stage II, III, and IV disease, respectively.
  • Poor response at the end of cytoreductive treatment and age younger than 4 years were poor prognostic factors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Developing Countries. Lymphoma, B-Cell / drug therapy. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, T-Cell / drug therapy
  • [MeSH-minor] Adolescent. Age Factors. Child. Child, Preschool. Female. Humans. Infant. Male. Retrospective Studies. Survival Analysis. Treatment Outcome. Turkey

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12197217.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Medvedev PV, Nikitin EA, Pivnik AV: [The therapeutic efficacy and toxicity of the liposomal form of daunorubicin (Daunoxome) in lymphosarcoma patients]. Ter Arkh; 2000;72(7):38-42
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The therapeutic efficacy and toxicity of the liposomal form of daunorubicin (Daunoxome) in lymphosarcoma patients].
  • AIM: To evaluate toxicity and efficacy of CDxOP regimen in the treatment of primary non-Hodgkin's lymphoma (PNHL).
  • MATERIAL AND METHODS: The study included 8 males and 6 females who had large B-cell lymphoma (n = 11), follicular lymphoma, predominantly large cell (n = 1), mantle cell lymphoma (n = 1) and peripheral T-cell lymphoma (n = 1).
  • PNHL stage IV, III and II was diagnosed in 7, 5 and 2 patients, respectively.
  • The other drugs were used in standard doses.
  • Three patients did not respond to therapy and died.
  • The results of the treatment are comparable with those of standard chemotherapy.
  • Further comparative studies are needed for determination of efficacy and maximal tolerated dose of daunoxome in combination with other drugs and irradiation, of long-term side effects.
  • This drug may be beneficial for elderly patients.
  • [MeSH-major] Antibiotics, Antineoplastic / administration & dosage. Daunorubicin / administration & dosage. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Female. Heart / drug effects. Humans. Liposomes. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / adverse effects. Remission Induction. Time Factors. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Lymphosarcoma.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10983319.001).
  • [ISSN] 0040-3660
  • [Journal-full-title] Terapevticheskiĭ arkhiv
  • [ISO-abbreviation] Ter. Arkh.
  • [Language] rus
  • [Publication-type] Clinical Trial; English Abstract; Journal Article
  • [Publication-country] RUSSIA
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Liposomes; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; ZS7284E0ZP / Daunorubicin; CHOP protocol
  •  go-up   go-down


32. Cao YB, Wang SS, Huang HQ, Xu GC, He YJ, Guan ZZ, Lin TY: [Primary breast lymphoma--a report of 27 cases with literature review]. Ai Zheng; 2007 Jan;26(1):84-9
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary breast lymphoma--a report of 27 cases with literature review].
  • BACKGROUND & OBJECTIVE: Primary breast lymphoma (PBL) is an uncommon disease with poor clinical outcome.
  • This study was to investigate clinicopathologic features and optimal treatment of PBL.
  • RESULTS: Of the 27 patients, 26 were women and 1 was man, with the age ranged from 12 to 84; 18 were at stage IE, 6 at stage IIE, and 3 at stage III/IVE; according to the WHO 2001 lymphoma classification system, 22 had B-cell lymphoma (including 17 cases of diffuse large B-cell lymphoma, 2 cases of mucosa-associated lymphoid tissue lymphoma, 1 case of marginal zone lymphoma, and 2 cases of unclassified B-cell lymphoma), 3 had peripheral T-cell lymphoma, and 2 had unclassified lymphoma.
  • Of the 27 patients, 8 received mastectomy and chemotherapy, 12 received excision of the breast lesion and chemotherapy (the 5-year overall survival rates were 23% and 58%, P=0.006), 5 received chemotherapy alone, and 2 received lesion excision alone; 24 achieved complete remission (CR) after scheduled treatment, 1 achieved partial remission (PR), and 2 patients had progressive disease (PD).
  • As to the 20 patients with high or moderate grade diseases (diffuse large B-cell lymphoma and peripheral T-cell lymphoma), the 5-year overall and disease-free survival rates were 48% and 27%, respectively.
  • CONCLUSIONS: The main subtypes of PBL are diffuse large B-cell lymphoma and peripheral T-cell lymphoma.
  • [MeSH-major] Breast Neoplasms / therapy. Lymphoma, Large B-Cell, Diffuse / therapy. Lymphoma, T-Cell / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Breast Neoplasms, Male / therapy. Child. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Mastectomy / methods. Middle Aged. Neoplasm Staging. Prednisone / therapeutic use. Survival Rate. Vincristine / therapeutic use. Young Adult

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17222374.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  • [Number-of-references] 14
  •  go-up   go-down






Advertisement